Clinical Trials Logo

Filter by:
NCT ID: NCT06238544 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: February 6, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm, open-label study. Patients with Paroxysmal Nocturnal Hemoglobinuria who had previously received and completed the HRS-5965 study well included. All eligible subjects received HRS-5965 tablets until the end of treatment in this study.

NCT ID: NCT06238518 Recruiting - De Novo Stenosis Clinical Trials

Intravascular Lithotripsy Versus Conventional Therapy for Severely Calcified Coronary Artery Lesions

REC-CHIPCAC
Start date: January 5, 2024
Phase: N/A
Study type: Interventional

Percutaneous coronary intervention (PCI) encounters challenges with calcified coronary lesions, leading to potential issues such as failed balloon dilatation, incomplete stent expansion, and increased risks of adverse events post-PCI, including stent restenosis and thrombosis. Intravascular lithotripsy (IVL), a novel approach for severely calcified coronary lesion preparation, has shown promising preliminary outcomes. Combining IVL with conventional approaches, such as Rotational atherectomy (RA), non-compliant balloons, or cutting balloons, may associated with additional benefit than conventional approaches only in terms of better stent expansion and lower long-term adverse events. This pilot randomized trial aims to investigate whether combining IVL to conventional therapy surpasses the efficacy of conventional approaches alone. The primary effectiveness endpoint is final stent expansion assessed by post-procedure optical coherence tomography (OCT), and the primary safety endpoint is target lesion failure (TVF). The trial seeks to provide valuable insights into the optimal approach for managing severely calcified coronary lesions during PCI.

NCT ID: NCT06238349 Recruiting - Clinical trials for Hyperbilirubinemia, Neonatal

Hyperbilirubinemia in Full-term Neonates

HFN
Start date: January 23, 2024
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of sunbathing and Bifidobacterium alone or in combination for full-term neonates with hyperbilirubinemia. The investigators hypothesize that the combination therapy of sunbathing plus Bifidobacterium is safe and effective for prevention and management of hyperbilirubinemia in full-term neonates. The investigators therefore design this prospective, randomized, controlled study to assess the preventive effects of sunbathing combined with Bifidobacterium supplementation on hyperbilirubinemia in full-term neonates. These observations may provide scientific evidence for the use of sunbathing and Bifidobacterium supplementation in the management of hyperbilirubinemia in full-term neonates.

NCT ID: NCT06238336 Recruiting - Clinical trials for Hematological Malignancy

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

Start date: June 15, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The trial is designed as an early exploratory single-centre, open, single-arm clinical trial. The trial is planned to evaluate the safety and efficacy of CAR-T for the treatment of relapsed refractory malignant haematological tumours. The trial is divided into five visit periods as follows: screening period, non-myeloablative pretreatment, short-term follow-up period, mid-term follow-up period and exit visit.

NCT ID: NCT06238232 Recruiting - Clinical trials for Primary Aldosteronism

Outcome of 68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Primary Aldosteronism

GAPA
Start date: January 9, 2024
Phase: N/A
Study type: Interventional

To compare the 68Ga-Pentixafor PET/CT and adrenal vein sampling on the long-term outcomes of primary aldosteronism (PA) patients with adrenal nodule (≥1cm)

NCT ID: NCT06238115 Recruiting - Clinical trials for Thromboembolic Events

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

TEAR
Start date: March 4, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To explore whether administering tirofiban in stent-assisted coiling/flow diverting treatments for participants with unruptured intracranial aneurysms can reduce new ischemic lesions on postoperative DWI sequences compared to conventional dual antiplatelet therapy.

NCT ID: NCT06238024 Recruiting - Ischemic Stroke Clinical Trials

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

IRIS
Start date: February 2, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

NCT ID: NCT06237790 Recruiting - Hearing Loss Clinical Trials

A Comparative Analysis of Speech Perception Between Cochlear Implant Patients and DFNB9 Patients Receiving Gene Therapy

Start date: April 6, 2024
Phase:
Study type: Observational

This cohort study aims to explore the trends and differences in multidimensional perceptual levels of patients after cochlear implants or gene therapy, as well as to comprehensively assess the efficacy of gene therapy for congenital deafness, thus providing a reference for making a well-rounded postoperative rehabilitation protocol for gene therapy patients.

NCT ID: NCT06237777 Recruiting - Clinical trials for Diabetic Macular Edema

A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This is a clinical study to evaluate the safety, tolerability and initial efficacy of SKG0106 intravitreal injection in diabetic macular edema (DME) patients.

NCT ID: NCT06237413 Recruiting - Solid Tumor Clinical Trials

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Start date: August 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.